According to VectivBio's latest financial reports the company has a price-to-book ratio of 4.96.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | 3.83 | 152.49% |
2021-12-31 | 1.52 | |
2020-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Organovo ONVO | 1.75 | -64.69% | ๐บ๐ธ USA |
Orchard Therapeutics
ORTX | 4.74 | -4.51% | ๐ฌ๐ง UK |
Novavax NVAX | -0.9224 | -118.60% | ๐บ๐ธ USA |
Novocure
NVCR | 4.21 | -15.07% | Jersey |